Zooming in on breast cancer reveals how mutations shape the tumour landscape
Scientists have created one of the most detailed maps of breast cancer ever achieved, revealing how genetic changes shape the physical tumour landscape, according to research funded by Cancer Research UK and published in Nature Cancer today (Monday).
An international team of scientists*, brought together by an ambitious £20 million Grand Challenge award from Cancer Research UK, has developed intricate maps of breast tumour samples, with a resolution smaller than a single cell.
These maps show how the complex cancer landscape – made up of cancer cells, immune cells and connective tissue – varies between and within tumours, depending on their genetic makeup.
This technique could one day provide doctors with an unparalleled wealth of information about each patient’s tumour upon diagnosis, allowing them to match each patient with the best course of treatment for them.
In the future, it could also be used to analyse tumours during treatment, allowing doctors to see in unprecedented detail how tumours are responding to drugs or radiotherapy. They could then modify treatments accordingly, to give each patient the best chance of beating the disease.
Dr Raza Ali, lead author of the study and junior group leader at the Cancer Research UK Cambridge Institute, said: “At the moment, doctors only look for a few key markers to understand what type of breast cancer someone has. But as we enter an era of personalised medicine, the more information we have about a patient’s tumour, the more targeted and effective we can make their treatment.”
The researchers studied 483 different tumour samples, collected as part of the Cancer Research UK funded METABRIC study, a project that has already revolutionised our understanding of the disease by revealing that there are at least 11 different subtypes of breast cancer.
The team looked within the samples for the presence of 37 key proteins, indicative of the characteristics and behaviour of cancer cells. Using a technique called imaging mass cytometry, they produced detailed images, which revealed precisely how each of the 37 proteins were distributed across the tumour.
The researchers then combined this information with vast amounts of genetic data from each patient’s sample to further enhance the image resolution. This is the first time imaging mass cytometry has been paired with genomic data.
These tumour ‘blueprints’ expose the distribution of different types of cells, their individual characteristics and the interactions between them.
By matching these pictures of tumours to clinical information from each patient, the team also found that the technique could be used to predict how someone’s cancer might progress and respond to different treatments.
Professor Carlos Caldas, co-author of the study from the Cancer Research UK Cambridge Institute, said: “We’ve shown that the effects of mutations in cancer are far more wide-ranging than first thought.
“They affect how cancer cells interact with their neighbours and other types of cell, influencing the entire structure of the tumour.”
The research was funded by Cancer Research UK’s Grand Challenge initiative. By providing international, multidisciplinary teams with £20 million grants, this initiative aims to solve the biggest challenges in cancer.
Dr David Scott, director of Grand Challenge at Cancer Research UK said: “This team is making incredible advances, helping us to peer into a future when breast cancer treatments are truly personalised.
“There’s still a long way to go before this technology reaches patients, but with further research and clinical trials, we hope to unlock its powerful potential.”
Notes to editor:
*The researchers where based at the Cancer Research UK Cambridge Institute, University of Cambridge, the University of Zürich, Switzerland and the British Columbia Cancer Research Centre, Canada.
Breast cancer is the most common type of cancer in the UK, with around 55,200 new cases each year. 78% women diagnosed with breast cancer in the UK survive their disease for 10 years or more.
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.